Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternatives to nitric oxide.

Stuart M Lowson1

  • 1Department of Anesthesiology, PO Box 800710, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA. SML4S@hscmail.mcc.virginia.edu

British Medical Bulletin
|November 9, 2004
PubMed
Summary

Inhaled nitric oxide (INO) offers selective pulmonary vasodilation for pulmonary hypertension (PH). Alternative inhaled therapies, including prostacyclins and phosphodiesterase inhibitors, are being explored due to INO

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How did we reform our out of control massive transfusion protocol program?

Transfusion·2021
Same author

Percutaneous coronary interventions and antiplatelet therapy in the perioperative period.

Journal of cardiothoracic and vascular anesthesia·2007
Same author

Does enteral glutamine supplementation decrease infectious morbidity?

Surgical infections·2006
Same author

Does the addition of glutamine to enteral feeds affect patient mortality?

Critical care medicine·2005
Same author

Inhaled alternatives to nitric oxide.

Critical care medicine·2005
Same author

Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery.

Critical care medicine·2002

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Medicine
  • Pharmacology

Background:

  • Inhaled nitric oxide (INO) is a selective pulmonary vasodilator used for pulmonary hypertension (PH) in adults and children.
  • Its effectiveness in managing PH with or without hypoxia is established.
  • Concerns regarding toxicity, cost, and negative outcomes necessitate exploring alternative treatments.

Purpose of the Study:

  • To review alternative therapeutic agents for pulmonary hypertension.
  • To discuss the potential of novel pharmacological approaches in managing PH.

Main Methods:

  • Review of existing literature on inhaled vasodilators and PH treatments.
  • Analysis of alternative agents including prostacyclin analogs and phosphodiesterase inhibitors.
  • Evaluation of emerging therapies targeting vasoconstrictor pathways.

Main Results:

  • Inhaled prostacyclin and prostaglandin analogs (iloprost, treprostinil, beraprost) are viable alternatives.
  • Phosphodiesterase inhibitors demonstrate significant potential for acute and chronic PH management.
  • Endothelin and thromboxane antagonists are under investigation for primary PH.

Conclusions:

  • Alternative inhaled therapies offer promising options for PH management.
  • Pharmacological advancements are expanding treatment strategies for various forms of PH.
  • Further research into novel agents like endothelin antagonists is crucial for long-term PH treatment.

Related Experiment Videos